Top Ten Unpartnered Drugs: Trying To Move Past Treating Symptoms In Neuroscience
This article was originally published in The Pink Sheet Daily
Executive Summary
Early-stage talent to be showcased at Windhover's Therapeutic Area Partnerships conference next week in Boston.
You may also be interested in...
"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
A generation of potentially useful drugs for neurologic disorders may be lost if something isn't done to shore up early stage companies being "strangled fiscally" by the shift in partnering and financing toward later-stage projects, says Harry Tracy, president of NI Research
"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
A generation of potentially useful drugs for neurologic disorders may be lost if something isn't done to shore up early stage companies being "strangled fiscally" by the shift in partnering and financing toward later-stage projects, says Harry Tracy, president of NI Research